NewAmsterdam Pharma announced positive results from its Phase 3 TANDEM clinical trial, showing a 48.6% reduction in LDL-C levels with a fixed-dose combination of obicetrapib and ezetimibe, significantly outperforming monotherapy and placebo. The trial involved 407 patients and met all co-primary endpoints, indicating strong efficacy and safety of the treatment.